WA
CCCC icon

Wasatch Advisors’s C4 Therapeutics CCCC Stock Holding History

Wasatch Advisors’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.5M Buy
3,522,644
+560,883
+19% +$1.92M 0.11% 123
2026
Q1 		$7.79M Sell
2,961,761
-1,383,157
-32% -$3.26M 0.05% 138
2025
Q4 		$8.3M Sell
4,344,918
-507,823
-10% -$1.2M 0.05% 153
2025
Q3 		$10.8M Sell
4,852,741
-2,571,921
-35% -$6.17M 0.06% 149
2025
Q2 		$10.6M Buy
7,424,662
+700,253
+10% +$1.02M 0.06% 154
2025
Q1 		$10.8M Buy
6,724,409
+651,808
+11% +$1.94M 0.06% 155
2024
Q4 		$21.9M Buy
6,072,601
+395,233
+7% +$1.97M 0.11% 130
2024
Q3 		$32.4M Buy
5,677,368
+830,218
+17% +$5M 0.16% 114
2024
Q2 		$22.4M Buy
4,847,150
+518,671
+12% +$3.09M 0.12% 123
2024
Q1 		$35.4M Sell
4,328,479
-2,810,470
-39% -$21.8M 0.18% 109
2023
Q4 		$40.3M Buy
7,138,949
+891,808
+14% +$2.03M 0.22% 101
2023
Q3 		$11.6M Sell
6,247,141
-952,350
-13% -$2.9M 0.07% 137
2023
Q2 		$19.8M Buy
7,199,491
+1,483,470
+26% +$4.77M 0.12% 129
2023
Q1 		$17.9M Sell
5,716,021
-59,677
-1% -$351K 0.11% 137
2022
Q4 		$34.1M Sell
5,775,698
-158,778
-3% -$1.32M 0.23% 97
2022
Q3 		$52M Buy
5,934,476
+267,818
+5% +$2.78M 0.36% 75
2022
Q2 		$42.7M Buy
5,666,658
+4,128,133
+268% +$36.3M 0.27% 94
2022
Q1 		$37.3M Buy
1,538,525
+243,063
+19% +$5.9M 0.18% 110
2021
Q4 		$41.7M Sell
1,295,462
-46,585
-3% -$1.84M 0.17% 120
2021
Q3 		$60M Sell
1,342,047
-47,442
-3% -$2.03M 0.24% 102
2021
Q2 		$52.6M Buy
1,389,489
+304,482
+28% +$10.9M 0.21% 100
2021
Q1 		$40.1M Buy
+1,085,007
New +$43.2M 0.18% 109

Other funds holding CCCC

CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
CA
CV Advisors Aventura, Florida $542M AUM 24.89% 1-Year Est. Return
NS
NBC Securities Birmingham, Alabama $1.48B AUM 31.07% 1-Year Est. Return
EL
EWA LLC Pittsbugh, Pennsylvania $548M AUM 35.14% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
OCWP
Owl Creek Wealth Partners Denver, Colorado $342M AUM
FFO
Fortitude Family Office Scottsdale, Arizona $516M AUM 28.38% 1-Year Est. Return

Wasatch Advisors's CCCC Position: Q2 2026 in Review

Wasatch Advisors increased its C4 Therapeutics (CCCC) stake by 19% in Q2 2026, buying an estimated $1.92M and bringing the position to 3,522,644 shares worth $16.5M. The position accounts for 0.11% of the portfolio, ranked #123.

Wasatch Advisors first reported a position in CCCC in Q1 2021 and has held it in 22 quarters since. The position peaked at $60M in Q3 2021. 8 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • Wasatch Advisors held 3,522,644 shares of C4 Therapeutics worth $16.5M as of Q2 2026.
  • Wasatch Advisors bought 560,883 C4 Therapeutics shares in Q2 2026, an estimated $1.92M.
  • C4 Therapeutics made up 0.11% of Wasatch Advisors's portfolio in Q2 2026, its #123 holding.
  • Wasatch Advisors first reported a position in C4 Therapeutics in Q1 2021 and has held it in 22 quarters since.
  • Wasatch Advisors's C4 Therapeutics position peaked at $60M in Q3 2021.
  • 8 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Wasatch Advisors's 13F filing for Q2 2026, filed 10 Jul 2026.